These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10800475)

  • 21. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
    Galmarini CM; Mackey JR; Dumontet C
    Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of DNA ligase I level by gemcitabine in human cancer cells.
    Sun D; Urrabaz R; Kelly S; Nguyen M; Weitman S
    Clin Cancer Res; 2002 Apr; 8(4):1189-95. PubMed ID: 11948132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.
    de Sousa Cavalcante L; Monteiro G
    Eur J Pharmacol; 2014 Oct; 741():8-16. PubMed ID: 25084222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evolving role for oral fluoropyrimidine drugs.
    Diasio RB
    J Clin Oncol; 2002 Feb; 20(4):894-6. PubMed ID: 11844808
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical, toxicological and pharmacological aspects of gemcitabine.
    Guchelaar HJ; Richel DJ; van Knapen A
    Cancer Treat Rev; 1996 Jan; 22(1):15-31. PubMed ID: 8625330
    [No Abstract]   [Full Text] [Related]  

  • 26. Gemicitabine resistence and mesenchymal phenotype.
    Inamoto T; Azuma H; Katsuoka Y
    Ann Surg Oncol; 2009 May; 16(5):1435-6. PubMed ID: 19184229
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).
    Lund B; Kristjansen PE; Hansen HH
    Cancer Treat Rev; 1993 Jan; 19(1):45-55. PubMed ID: 8431926
    [No Abstract]   [Full Text] [Related]  

  • 28. [Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].
    Ohkawa S
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():198-202. PubMed ID: 16457249
    [No Abstract]   [Full Text] [Related]  

  • 29. Gemcitabine: novel combination of efficacy and tolerability.
    Anticancer Drugs; 1993 Dec; 4(6):671. PubMed ID: 8298167
    [No Abstract]   [Full Text] [Related]  

  • 30. Gemcitabine and small cell lung cancer.
    Scarpati MD; Vicidomini G; Santini M
    Lung Cancer; 2001 Nov; 34(2):313-4. PubMed ID: 11679191
    [No Abstract]   [Full Text] [Related]  

  • 31. Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer.
    Liu QH; Yong HM; Zhuang QX; Zhang XP; Hou PF; Chen YS; Zhu MH; Bai J
    Invest New Drugs; 2020 Apr; 38(2):350-359. PubMed ID: 31124054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar changes were induced by Cladribine and by gemcitabine, in the deoxypyrimidine salvage, during short-term treatments.
    Csapó Z; Keszler G; Sasvári-Székely M; Smid K; Noordhuis P; Peters GJ; Staub M
    Adv Exp Med Biol; 1998; 431():525-9. PubMed ID: 9598122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
    Jordheim LP; Galmarini CM; Dumontet C
    Bull Cancer; 2005 Mar; 92(3):239-48. PubMed ID: 15820918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine--a major advance?
    Thomas A; Steward WP
    Ann Oncol; 1998 Dec; 9(12):1265-7. PubMed ID: 9932153
    [No Abstract]   [Full Text] [Related]  

  • 35. Gemcitabine for lung cancer.
    Drug Ther Bull; 1996 Sep; 34(9):71-2. PubMed ID: 8885499
    [No Abstract]   [Full Text] [Related]  

  • 36. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
    Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
    Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical pharmacology of nucleoside analogues].
    Milano G; Chamorey AL; Thyss A
    Bull Cancer; 2002 Aug; 89 Spec No():S71-5. PubMed ID: 12449033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
    Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
    Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
    Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
    J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.